Last $22.06 USD
Change Today -0.20 / -0.90%
Volume 140.6K
PRTA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

prothena corp plc (PRTA) Snapshot

Open
$22.70
Previous Close
$22.26
Day High
$22.70
Day Low
$21.95
52 Week High
03/20/14 - $49.24
52 Week Low
08/1/14 - $16.71
Market Cap
604.1M
Average Volume 10 Days
204.2K
EPS TTM
$-0.16
Shares Outstanding
27.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROTHENA CORP PLC (PRTA)

Related News

No related news articles were found.

prothena corp plc (PRTA) Related Businessweek News

No Related Businessweek News Found

prothena corp plc (PRTA) Details

Prothena Corporation plc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of novel antibodies for the treatment of various diseases associated with protein misfolding or cell adhesion. Its product pipeline includes NEOD001, a product candidate in Phase 1 clinical trial to target AL and AA forms of amyloidosis; PRX002 for the treatment of Parkinson’s disease and related synucleinopathies; and PRX003 for the treatment of inflammatory disease and metastatic cancers. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dublin, Ireland.

39 Employees
Last Reported Date: 03/7/14
Founded in 2012

prothena corp plc (PRTA) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $462.1K
Chief Financial Officer
Total Annual Compensation: $278.8K
Chief Scientific Officer and Head of Research...
Total Annual Compensation: $349.2K
Chief Business Officer
Total Annual Compensation: $265.3K
Compensation as of Fiscal Year 2013.

prothena corp plc (PRTA) Key Developments

Prothena Corporation plc Announces Unaudited Consolidated Financial Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Cash Flow Guidance for the Year of 2014

Prothena Corporation plc announced unaudited consolidated financial results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenue of $1.486 million against $0.171 million a year ago. Loss from operations was $13.132 million against $9.566 million a year ago. Loss before income taxes was $12.941 million against $9.552 million a year ago. Net loss was $13.182 million or $0.48 per diluted share against $9.689 million or $0.55 per diluted share a year ago. The company reported net cash used in operating activities of $12.3 million in the third quarter of 2014. For the nine months, the company reported total revenue of $48.841 million against $0.509 million a year ago. Income from operations was $6.456 million against loss from operations of $29.725 million a year ago. Income before income taxes was $6.648 million against loss before income taxes of $29.675 million a year ago. Net income was $5.960 million or $0.24 per diluted share against net loss of $29.942 million or $1.69 per diluted share a year ago. The company reported net cash provided by operating activities of $11.8 million for the first nine months of 2014. The company continues to expect a net cash burn from operating activities of $7 to $12 million for 2014, and now expects to end the year with approximately $285 million in cash (mid-point). The estimated 2014 net cash burn from operating activities is primarily driven by an estimated net loss of $13 to $18 million, which includes an estimated $6 million of non-cash share-based compensation expense.

Prothena Corporation plc Presents at JMP Securities Boston Biotechnology Day, Sep-05-2014

Prothena Corporation plc Presents at JMP Securities Boston Biotechnology Day, Sep-05-2014 . Venue: The Langham Hotel, Boston, Massachusetts, United States.

Prothena Corporation plc Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Year 2014

Prothena Corporation plc reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company's total revenue was $15,121,000 compared to $167,000 a year ago. Income from operations was $1,569,000 compared to loss from operations of $11,192,000 a year ago. Income before income taxes was $1,586,000 compared to loss before income taxes of $11,178,000 a year ago. Net income was $1,290,000 compared to net loss of $11,302,000 a year ago. Net income per share attributable to holders of ordinary shares - diluted was $0.06 compared to loss of $0.64 a year ago. For the six months, the company's total revenue was $47,355,000 compared to $338,000 a year ago. Income from operations was $19,588,000 compared to loss from operations of $20,159,000 a year ago. Income before income taxes was $19,589,000 compared to loss before income taxes of $20,123,000 a year ago. Net income was $19,142,000 compared to net loss of $20,253,000 a year ago. Net income per share attributable to holders of ordinary shares - diluted was $0.83 compared to loss of $1.15 a year ago. The company continues to expect a net cash burn from operating activities of $7 to $12 million for 2014, and now expects to end the year with approximately $285 million in cash (mid-point). The estimated 2014 net cash burn from operating activities is primarily driven by an estimated net loss of $13 to $18 million, which includes an estimated $6 million of non-cash share-based compensation expense.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRTA:US $22.06 USD -0.20

PRTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRTA.
View Industry Companies
 

Industry Analysis

PRTA

Industry Average

Valuation PRTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.3x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROTHENA CORP PLC, please visit www.prothena.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.